![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
252 episodes
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
BioCentury This Week BioCentury
-
- Science
-
-
5.0 • 13 Ratings
-
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
-
Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs
Alpha emitters are the latest trend in the hot radioligand space, but there’s debate about which isotope offers the best attributes for optimizing safety and efficacy. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the benefits and challenges that come with developing radiopharmaceuticals using lead-212 versus its more well-known counterpart actinium-225. They also discuss Editor-in-Chief Simone Fishburn’s conversation with Susan Galbraith, EVP of Oncology R&D at...
-
Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns
Buysiders are upbeat headed into the back half of the year, but uncertainty over the Federal Reserve’s timing on interest rate cuts is keeping that sentiment in check. On the latest BioCentury This Week podcast, BioCentury’s editors preview the public markets’ second half of 2024, discussing the appetite for biotech IPOs and M&A and what investors are looking for as they read the Fed tea leaves.They also discuss Congress’ FDA budget squeeze, the growing momentum of the Biosecure Act — whi...
-
Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure
The U.K.’s life sciences ecosystem boasts “palpable energy at the very innovation end of the spectrum in biotech, with a lot of really quality science,” BioCentury Editor in Chief Simone Fishburn says on the latest BioCentury This Week podcast. Fishburn assesses the maturation of the country’s biotech industry, including the need for an influx of capital to catalyze the sector’s growth. Washington Editor Steve Usdin discusses the latest developments for the Inflation Reduction and the Biosecu...
-
Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner
The impact on FDA and the biopharma industry of the Supreme Court’s move to overturn the legal doctrine that courts defer to federal agencies’ interpretations of ambiguous laws will take years to come into focus; for now, the clearest effects of the Chevron ruling will be on disputes over exclusivity and other non-science issues. On the latest BioCentury This Week podcast, BioCentury’s editors analyze the court’s decision, including how FDA could adjust how it operates. The editors also discu...
-
Ep. 239 - Rare Disease Spotlight: MPS & DMD
A biomarker breakthrough could shave years off the development of therapies for a group of devastating, progressive ultrarare diseases. On the latest BioCentury This Week podcast, BioCentury’s editors discuss FDA’s agreement to allow biopharma companies to use a biomarker as the basis for accelerated approval of neuronal mucopolysaccharidoses therapies, which marks an important inflection point, both for MPS and rare diseases in general. The editors also assess FDA’s decision to grant full ap...
-
Ep. 238 - Biosecure Act: The Impact & What's Ahead
After whisking through Washington for the first half of the year, raising alarms, mutating and causing confusion, the Biosecure Act is now on pause. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the delay for the legislation, which seeks to drive Chinese contract development and manufacturing organizations out of the U.S., means, what will happen next, and how it will impact life sciences companies.View full story: https://www.biocentury.com/article/65277103:09...
Customer Reviews
Simone Fishburn!!!!
Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!